# Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

> **NCT01850004** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 84 (actual)

## Conditions studied

- Chronic Phase Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01850004
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-22
- **Primary completion:** 2017-09-20
- **Final completion:** 2021-10-08
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2022-11-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01850004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01850004, "Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01850004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*